Interestingly, in the ER-positive/HER2-negative subtype, which is generally known to have the least immunogenicity and lowest proliferation among all breast cancer subtypes, TIL-high tumors were particularly associated with higher immune response, mutation rates, and cell proliferation compared with TIL-low tumors. Here, ERBB2 is linked to breast cancer.